Pharma companies are constantly struggling to replace products that face loss of exclusivity (LoE) with a promising pipeline, and Otsuka Pharmaceutical Co. Ltd.’s acquisition deal for US biotech Jnana Therapeutics Inc. seems one such move.
Jnana’s in-house pipeline of small molecules focuses on oral drugs for phenylketonuria
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?